CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
异体 CAR-T 进展：平台、当前进展与局限性
英文原题：Allogeneic CART progress: platforms, current progress and limitations.
查看英文原题
Allogeneic CART progress: platforms, current progress and limitations.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
同种异体CAR-T（CAR-T）细胞相比自体T细胞疗法具有优势，例如可获得用于生产的细胞、合适的HLA匹配供者（如果要避免移植物抗宿主病和排斥反应，并且自体CAR-T 细胞过程中转导方法相关风险更低）。近年来，附加编辑和非编辑技术正在帮助使同种异体CAR-T 疗法成为有希望的未来治疗。通用即用型CAR-T 细胞可以解决的关键问题包括预防移植物抗宿主病（GVHD）、耗时以及同种异体CAR-T 细胞面临的其他挑战。在此，我们重点介绍了CAR-T 开发的改进，特别是在工程化同种异体CAR-T 方面、与此相关的临床实践、临床前和临床研究，以及它们在过去10年中关于同种异体CAR-T 细胞治疗血液系统恶性肿瘤和癌症所研究的成功。
展开英文摘要原文
Allogenic chimeric antigen receptor T (CAR-T) cells have advantages compared to autologous T cell therapies such as availability cells for production, a suitable HLA-matched donor (if graft-vs-host-disease and rejection effects are to be avoided and also lower risks associated with transduction methods in process of autologous CAR-T cells).
In recent years, the additional editing and non-editing technologies are helping to make allogenic CAR-T therapies a hopeful future treatment. Universal off-the-shelf CAR-T cells can be solved key issues include preventing graft-versus-host disease (GVHD) and time consumption and other challenges faced to allogenic CAR-T cells.
Here, we have highlighted the improvement in CAR-T development, particularly in engineering allogenic CAR-T, clinical practices related to these, pre-clinical and clinical studies and their successes which investigated in recent 10 years related to treatment of hematological malignancies and cancers by allogenic CAR-T cells.
论文信息
- 作者
- Shokati A、Sanjari-Pour M、Akhavan Rahnama M、Hoseinzadeh S、Vaezi M、Ahmadvand M
- 第一作者单位
- Department of Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.Iran
- 通讯作者单位
- Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran.Iran
- 文献类型
- 综述
- 期刊
- Frontiers in immunology2025
- 原文标识
- PubMed 40574859 · DOI 10.3389/fimmu.2025.1557157
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →